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ABSTRACT
Introduction While multiple pharmacological and 
non- pharmacological interventions treating chronic 
non- specific low back pain (CLBP) are available, they 
have been shown to produce at best modest effects. 
Interventions such as repetitive transcranial magnetic 
stimulation (rTMS), a form of non- invasive brain 
stimulation, have exhibited promising results to alleviate 
chronic pain. However, evidence on the effectiveness of 
rTMS for CLBP is scarce due to limited rigorous clinical 
trials. Combining rTMS with motor control exercises 
(MCE) may help to address both central and nociceptive 
factors contributing to the persistence of LBP. The primary 
aim of this randomised controlled trial is to compare 
the effectiveness of a combination of rTMS and MCE 
to repeated rTMS sessions alone, sham rTMS and a 
combination of sham rTMS and MCE on pain intensity.
Methods and analysis One hundred and forty 
participants (35/group) with CLBP will be randomised 
into four groups (active rTMS+MCE, sham rTMS+MCE, 
active rTMS and sham rTMS) to receive 10 sessions of 
their allocated intervention. The primary outcome will be 
the pain intensity, assessed at baseline, 4, 8, 12 and 24 
weeks. Secondary outcomes will include disability, fear 
of movement, quality of life and patient global rating of 
change.
Ethics and dissemination Ethics approval was obtained 
from the Comité d’éthique de la recherche sectoriel en 
réadaptation et intégration sociale, CIUSS de la Capitale 
Nationale in June 2019 (#2020–1844 – CER CIUSSS- CN). 
The results of the study will be submitted to a peer- 
reviewed journal and scientific meetings.
Trial registration number NCT04555278.
BACKGROUND
Chronic low back pain (CLBP) produces an 
enormous individual, social and economic 
burden. CLBP is often associated with 
disability, fear of movement/injury1 and with 
a decreased quality of life.2 The prevalence 
of the disease is still rising3 as interventions 
prescribed to alleviate CLBP (eg, medication, 
exercise and surgery) have been shown to 
produce at best modest effects.4–6 Refractori-
ness to treatment could in part be explained 
by dysfunction of the pain modulation system 
within the central nervous system. Changes 
in the organisation or function of cerebral 
areas involved in pain modulation such as 
the dorsolateral prefrontal cortex, cingu-
late cortex and insula have been reported in 
people with CLBP (for a review, see ref 7). 
These regions are rich in opioid receptors8 
and contribute to the descending control of 
nociceptive inputs through projections to the 
brainstem (eg, periaqueductal grey matter). 
Alterations in these brain structures could 
Strengths and limitations of this study
 ► This is the first powered randomised controlled trial 
investigating the effectiveness of repetitive tran-
scranial magnetic stimulation (rTMS) on chronic low 
back pain (CLBP).
 ► This study will provide both short- term and long- 
term effect of treatment using a 6- month follow- up.
 ► Participants and therapists providing the exercises 
will be blinded to the rTMS group allocation (active 
or sham).
 ► A limitation of this trial is the absence of blinding of 
the investigator providing the rTMS sessions.
 ► Given our recruitment strategies, our study sample 
may not fully represent the CLBP population treated 
in clinical practice.
 on M









pen: first published as 10.1136/bm





2 Patricio P, et al. BMJ Open 2021;11:e045504. doi:10.1136/bmjopen-2020-045504
Open access 
contribute to reduced efficacy of descending pain inhibi-
tion and amplification of nociception in CLBP.9 10
Interventions with a capacity to activate the pain modu-
lation system, such as non- invasive brain stimulations 
(NIBS), could contribute to alleviation of CLBP. Among 
NIBS techniques, transcranial magnetic stimulation 
(TMS) represents a non- painful approach that can depo-
larise neurons within the cortex under the stimulating 
coil.11 In contrast to electrical stimulation, the area of 
stimulation is relatively small and allows targeting of rela-
tively specific cortical areas.11 Moreover, application of 
TMS in a repetitive manner (rTMS) at different frequen-
cies can influence the corticospinal excitability and the 
networks’ function of the targeted cortical areas.12 Thus, 
because of all these advantages, rTMS has become one of 
the most studied interventions to influence brain func-
tion13 with a particular focus on the primary motor cortex 
(M1).
Although the full scope of mechanisms through 
which rTMS modifies brain function is not yet clear, it is 
believed that rTMS can induce pain relief partly through 
the release of opioids,14 via reciprocal corticothalamic 
connections14–17 and by a potential remote action on 
anterior cingulate and insular cortices.14 rTMS might 
have the capacity to influence neural networks involved 
in pain modulation and could induce pain relief in CLBP.
Repetitive TMS has been widely used in research envi-
ronments to treat individuals with chronic pain who 
are refractory to conventional therapy.18 19 Results of 
recent meta- analyses point towards a significant reduc-
tion of neuropathic pain (eg, pain associated with nerve 
injury or neurological lesion) using high- frequency 
rTMS.18 19 Evidence for rTMS efficacy in alleviating non- 
neuropathic pain, including CLBP, is scarce as most clin-
ical trials that have evaluated NIBS in CLBP have used 
transcranial direct current stimulation (tDCS, which is 
another type of NIBS) with the anode electrode posi-
tioned over M1. A recent meta- analysis from our group 
identified moderate quality evidence that tDCS does not 
lead to improved long- term pain and disability in CLBP 
(Patricio et al. The effect of non- invasive brain stimulation to 
reduce non- specific low back pain: a systematic review and meta- 
analysis, accepted in Clin J Pain), but two studies that 
evaluated the efficacy of rTMS for CLBP were found: a 
non- randomised clinical trial (n=10, cross- over design) 
reported a significant reduction in pain after one session 
of high- frequency rTMS compared with a sham stimula-
tion.20 A randomised controlled trial (RCT) (n=44 and 
n=12, respectively, for active and sham rTMS) reported 
that 13 sessions of rTMS induced a larger pain reduc-
tion than exercise therapy or transcutaneous electrical 
nerve stimulation applied to the back.21 The latter study 
had high risk of bias (eg, open- label design, missing 
information about stimulation parameters and statistical 
analysis), and results should be interpreted with caution. 
Preliminary evidence of the effect of rTMS on CLBP 
appears promising, but high- quality clinical trials are 
needed to confirm these results.
Although early evidence suggests rTMS can induce 
pain relief, the effect attenuates with time and repeated 
sessions may be essential to produce long- lasting 
effects.17 22 Combining NIBS with conservative CLBP 
treatments might be an effective intervention to enhance 
the treatment effect.23 Exercise therapy is the most 
recommended conservative intervention for CLBP within 
clinical practice guidelines.24 Within a wide range of exer-
cise therapy, motor control exercises (MCE) have been 
extensively studied, with evidence of small to moderate 
effect size on pain at short, intermediate and long- term 
follow- up compared with minimal intervention.25 This 
exercise approach aims to improve spine health by opti-
mising spine loading. Since MCE is believed to address 
mechanical components of CLBP by minimising nocicep-
tive inputs through a reduction in sensitisation related 
to poor movement patterns26 and rTMS may impact on 
the efficacy of central pain modulation mechanisms, the 
combination has the potential to address the multifacto-
rial nature of CLBP.
Objectives and hypothesis
Our primary objective is to compare the effectiveness 
of repeated sessions of active rTMS, sham rTMS, active 
rTMS+MCE and sham rTMS+MCE on pain intensity in 
patients with CLBP. Secondary objectives are to compare 
the effectiveness of these interventions on disability, fear 
of movement, quality of life and patient global rating of 
change. We hypothesise that the combination of rTMS 
and MCE will produce larger improvements for all 
outcomes at the end of the intervention period and at 6 




This parallel group RCT with a pseudofactorial design 
(ie, no exercise instead of sham exercise) will include 
five evaluation sessions over 24 weeks (baseline, 4, 8, 
12 and 24 weeks) and 10 sessions of treatment over 8 
weeks (figure 1). All participants will take part in one 
session prior to the 10 sessions of treatment to deter-
mine rTMS parameters (see Interventions). During the 
baseline evaluation session, included participants will 
complete self- administered questionnaires on sociode-
mographic characteristics, comorbidities, pain intensity, 
disability and quality of life at baseline. Then, they will 
be randomly assigned to one of four intervention groups 
(active rTMS, active rTMS+MCE, sham rTMS and sham 
rTMS+MCE) and undergo the assigned intervention. 
Treatment will commence with a 1- week induction phase 
(ie, a phase with multiple sessions in a short period of 
time to enhance the effects of rTMS at the beginning of 
the treatment) as recommended for studies using rTMS 
as an analgesic therapy.27 This will involve three sessions 
within a week. For the subsequent 7 weeks, participants 
will undertake a maintenance phase with one session 
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per week. Study outcomes will be evaluated again at all 
subsequent follow- ups. The study will be conducted at 
the Centre interdisciplinaire de recherche en réadaptation et en 
intégration sociale (Cirris). This RCT is registered on  Clin-
icalTrials. gov and will follow the CONSORT guideline.28
Participants
Four groups of 35 adults (≥18 years old) with CLBP 
(ie, pain in the low back area with or without leg pain 
below the knee limiting activities or daily routine that 
has been present for more than 3 months)29 will be 
recruited. Potential participants will be reached through 
the mailing list of the Université Laval’s community, the 
Quebec Back Pain Consortium’s database (patients who 
have accepted to be contacted for research project on low 
back pain), advertisement at primary care clinics and by 
referrals from physicians. Participants will be included 
if they report an average pain intensity of at least 3 out 
of 10 during the preceding week on a pain numerical 
rating scale (PNRS; anchored with ‘no pain’ at zero and 
‘worst pain imaginable’ at 10) and at least 10 points on 
the Oswestry disability index (ODI). These criteria are 
based on the clinically important differences on PNRS (2 
points)30 and ODI (10 points)31 and were chosen in order 
to include participants that are likely to benefit from the 
interventions as well as allowing the observation of clini-
cally important differences following interventions. Partic-
ipants will be excluded if they present with an identified 
cause of pain like neuropathic pain (if score ≥4 on the 
Douleur Neuropathique 4 questionnaire)32 or a serious 
spinal pathology (eg, fracture, tumour and spinal infec-
tion), a history of back surgery or a major neurological, 
cardiovascular or psychiatric illness (eg, major psychosis 
and major depression) and if they currently use MCE to 
treat their LBP. Participants will also be excluded if they 
had previously experienced rTMS and if they present 
with any specific rTMS- related exclusion criteria such as 
previous seizure/convulsion, cochlear implant and preg-
nancy (for full list of contraindications for rTMS, see refs 
33 34).
Randomisation/blinding
A randomisation list will be generated using a computer 
random number generator by an independent research 
assistant. Consecutive numbered sealed opaque enve-
lopes will be used to guarantee concealment of alloca-
tion. Participants will be randomised 1:1:1:1 to receive 
either rTMS active or sham, with or without exercises, 
and stratified by sex and pain- related disability (score 
below or above 20 points on ODI). All outcomes will be 
assessed through an online procedure using Research 
Electronic Data Capture (REDCap), a secure web- based 
software designed to support data capture for research 
studies,35 ensuring that no assessor could bias the data 
collection. The researcher who will analyse the data will 
be blinded to the allocation. The participants and phys-
ical therapists providing the exercises will be blinded on 
the allocation of rTMS. The effectiveness of blinding 
will be evaluated at the end of the 24- week follow- up. To 
evaluate its effectiveness, the participants and therapists 
providing the MCE will answer the following question: 
what rTMS intervention do you think the participant 
received?, with one of the following answers: (1) active 
rTMS, (2) sham rTMS or (3) don’t know. If they answer 1 
or 2, they will be requested to explain why they think they 
received this intervention. Participants will be asked to 
not describe their sensation during rTMS or their opinion 
of what group they are in during the MCE sessions to 
avoid unblinding the assessor and therapist. Emergency 
unblinding will occur only if severe side effects occur (eg, 
Figure 1 Flow chart of the study process. MCEs, motor control exercises; rTMS, repetitive transcranial magnetic stimulation.
 on M









pen: first published as 10.1136/bm





4 Patricio P, et al. BMJ Open 2021;11:e045504. doi:10.1136/bmjopen-2020-045504
Open access 
seizure) and if the participant’s physician needs to know 
the group allocation for safety reasons. The emergency 
unblinding will be realised by a person not involved in 
the project. The actual allocation will not be disclosed to 
study personnel and will be disclosed to the patient only 
if deemed necessary.
Interventions
Evaluation session (rTMS parameters)
All participants will attend one session before the 10- session 
intervention to determine rTMS parameters (hotspot 
and motor threshold). A figure- of-8 coil and a biphasic 
Magstim Rapid 2 stimulator (The MagstimCo, Whitland, 
UK) will be used. Coil orientation and position will be 
guided throughout the experiment by a neuronavigation 
system (Brainsight, Rogue research, Montreal, Quebec, 
Canada). The hotspot and the resting motor threshold 
(RMT) of the first dorsal interosseous (FDI) muscle will 
be measured with electromyography electrodes placed 
over this muscle. The position of the hotspot will be saved 
by the neuronavigation system enabling a quick reposi-
tioning of the coil at each following session of treatment.
Repetitive transcranial magnetic stimulation
At each session, the hotspot and the RMT will be 
confirmed and/or adjusted. The intensity of rTMS will 
be set at 95% of the hand RMT. Previous studies of 
patients with CLBP20 and fibromyalgia17 have achieved 
significant reduction in clinical pain using these param-
eters (including stimulating hand M1 hotspot). For 
safety reasons, it is not possible to use the RMT of the 
back muscles because this requires very high intensity 
of stimulation at rest (100% of stimulator), which would 
result in very high rTMS intensity, that increases the risk 
of seizure.33 36 Active rTMS will consist of 40 trains of 5 s 
each at 10 Hz (25 s intertrain interval) applied over the 
primary motor cortex (M1) at the location that evokes 
the largest response of FDI cortical representation, for a 
total of 2000 stimulations over a period of 20 min.17 This 
aligns with current guidelines that recommend at least 
1000 stimulations of high- frequency rTMS to produce 
pain relief18 and remains within safety margin.33
Sham rTMS
A sham coil will be used to ensure the blinding of partic-
ipants. This coil is the same as a regular rTMS coil but is 
equipped with a magnetic shield that blocks the magnetic 
field. It will provide auditory effects similar to the active 
coil.37 At each session, the position of the participant’s 
hotspot will be displayed by the neuronavigation system, 
and the sham coil will be placed over it. We believe that 
the use of the neuronavigation system will permit to 
enhance the credibility of the sham session (eg, precise 
positioning of the coil, use of state- of- the- art equipment 
and so on) and will help to blind participants allocated 
to sham rTMS. In addition, our paradigm has several 
advantages since it ensures that the placebo is: (1) inert 
(the shield stops all stimulations) and (2) structurally 
equivalent (ie, same number of sessions and duration 
of the session). We will also recruit participants that are 
naïve to rTMS (ie, they do not know the sensation of a 
true treatment). These specific characteristics of the 
sham design will improve blinding of the participants.38
Motor control exercise
The two groups combining active or sham rTMS to MCE 
(active rTMS+MCE and sham rTMS+MCE) will receive 
the same rehabilitation program that will consist of a 
30 min session of MCE following the rTMS intervention 
(three times during the induction week and then once 
a week for the following 7 weeks). An experienced phys-
iotherapist will deliver the MCE according to the princi-
ples outlined by Hodges et al.39 The first session will begin 
with an evaluation of the participant’s abilities and defi-
ciencies in posture, movement and muscle activation to 
design a tailored training program individually for each 
participant. Spinal alignment, muscle activity/stiffness 
and control, movement patterns, regions adjacent to the 
lumbar spine such the hip and pelvic floor, associated 
functions such as breathing pattern and symptoms will be 
considered in the clinical examination. Motor learning 
principles will be used to address sensorimotor function 
related to the participant’s presentation on assessment, 
such as restoration of optimal trunk muscle coordina-
tion and control, encouraging pain- free posture and 
movement and progression to functional activities.40–42 
External feedback will be given by the physiotherapist at 
every stage of the rehabilitation, and participants will be 
encouraged to repeat their exercises as often as possible, 
with sufficient repetition and intensity to enhance 
experience- dependent plasticity43 (eg, daily exercises 
with four series of 10 repetitions). External feedback will 
be reduced with improvement in the performance of the 
exercises. An emphasis on the quality of the contraction 
of deep muscles of the trunk (eg, transversus abdominis, 
lumbar multifidus), static and dynamic progression of 
spine and lumbopelvic orientation and movement and a 
functional re- education specific to participant goals will 
be made. Complexity will be added following the partic-
ipant’s progression with increasing the load, modifying 
the body position or adding dynamic movement. The 
exercises will be reported according to the Consensus 
on Exercise Reporting Template.44 Participants will be 
encouraged to perform daily (~30 min) three to five home 
exercises adapted to their condition and will complete an 
exercise log to evaluate adherence. Although not manda-
tory, participants will be invited to continue their exer-
cises on their own after the 8- week intervention period.
Outcomes
Recommendations from an expert consensus on the best 
instrument measurements (‘Core outcomes’) for clinical 
trials in LBP will be followed to measure pain, disability 
and health- related quality of life domains.45 Recommen-
dations are based on the quality of psychometric prop-
erties of the instruments (eg, reliability and validity), 
 on M
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ease of use and availability. Study outcome measures are 
presented in table 1 according to the SPIRIT guideline.46
Primary outcome
As pain is usually the main concern of people with CLBP,47 
our primary outcome will be the average pain intensity 
over the last week, assessed on a 11- point PNRS ranging 
from 0 to 10, anchored with ‘no pain’ at zero and ‘worst 
pain imaginable’ at 10. Pain assessment using the PNRS 
has been suggested as a core outcome for individuals with 
LBP.48 This rating scale has an excellent reliability (intra-
class correlation coefficient (ICC)=0.92)49 and a clinically 
important difference (CID) of 2 points.30
Secondary outcomes
We will evaluate pain- related disability using the ODI 
V.2.1, which is a self- administered questionnaire based on 
the evaluation of pain elicited during the performance 
of 10 activities (eg, personal care, lifting, walking and 
sleeping).50 ODI is valid, reliable and responsive to treat-
ment for patients with CLBP51 with an ICC of 0.8452 and 
a CID of 10.31
Quality of life will be assessed using the SF-12, a generic 
quality- of- life questionnaire that consists of 12 questions 
evaluating eight mental and physical health domains (eg, 
physical functioning, general health, social functioning 
and mental health).53 It is valid and reliable (Cronbach’s 
alpha above the recommended level of 0.70)54 in CLBP.51
Pain- related fear of movement will be evaluated by the 
Tampa scale for kinesiophobia (TSK). The original TSK is a 
17- item questionnaire in which respondents have to indicate 
their agreement with the items on a 4- point Likert scale.55 
However, the scores on items 4, 8, 12 and 16 are reversed, 
and patients may encounter difficulties in interpreting these 
questions.56 Thus, the 13- item version of the TSK (the reverse 
items are deleted) will be used, and it has shown an increased 
test–retest reliability (r=0.79) and internal consistency (Cron-
bach’s alpha of 0.76)56 compared with TSK-17. This question-
naire will allow to explore the effect of our interventions on a 
pain- related fear of movement.
The perception of the participants’ improvement or 
deterioration after the intervention will be assessed using 
an 11- point global rating of change scale, ranging from −5 
(very much worse) to 5 (completely recovered), with 0 for 
‘unchanged’.57 This scale has a high test–retest reliability 
(ICC=0.90), an MDC of 0.45 points and a CID of 2 points.57
Sample size
Our sample was estimated using the CID for pain inten-
sity (2 points)30 and the standard deviation reported from 
a study that used a combination of transcranial direct 
current stimulation and exercise (3.0).58 Considering an 
alpha of 0.05, a beta of 0.20 and 20% of dropout, a sample 
size of 140 participants (35 per group) was calculated 
using G*Power V.3.1.9 software.
Statistical analysis
Table 2 represents the pseudofactorial design (rTMS × 
MCE) used in our RCT. Generalised linear mixed models 
(GLMM) will be performed using terms for rTMS (active 
Table 1 SPIRIT diagram of enrolment, interventions and assessments for the ExTraStim trial
Timepoint
Enrolment Baseline First treatment Post first treatment
−t2 −t1 0 w4 w8 w12 w24
Enrolment   
Initial screening ×           
Eligibility assessment ×           
Informed consent ×           
Treatment allocation   ×         
Interventions   
Active rTMS     
   
    
Sham rTMS     
   
    
Active rTMS+MCE     
   
    
Sham rTMS+MCE
   
Assessments   
Baseline demographic information ×           
PNRS   × × × × ×
ODI   × × × × ×
SF-12   ×   × × ×
TSK   ×   × × ×
GRC       ×     
0, starting day of the treatment; GRC, global rating of change; MCE, motor control exercises; ODI, Oswestry Disability Index; PNRS, pain numerical rating scale; rTMS, repetitive 
transcranial magnetic stimulation; SF-12, 12- Item Short Form Survey; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; t1, baseline evaluation; t2, first 
contact with participants; TSK, Tampa scale of kinesiophobia; w4–w24, weeks 4–26.
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vs sham), MCE (yes vs no), time (0, 4, 8, 12 and 24 weeks) 
and all interactions between terms with random effect 
for participants. GLMM will be apply on both primary 
(pain) and secondary (disability, quality of life and kine-
siophobia) outcomes. The rTMS × MCE × time interac-
tions will inform if there is a benefit to combine both 
treatments.
If a violation in assumptions allowing the use of GLMM 
occurs (eg, a change in the types of data distribution 
between the different time points), a non- parametric 
longitudinal data (nparLD) analysis will be performed 
as this procedure provides robust rank- based methods, 
even in case of an unknown distribution or atypical 
measurements and outliers.59 Both GLMM and nparLD 
work well with missing data without any need to impute 
or reject participants. The significance threshold will be 
set at p<0.05. Participants will be asked to report any side 
effects that occurred during the study.
Patient and public involvement
A patient partner (Laurent Dupuis) reviewed the study 
design considering the perspective of a patient. Main 
results will be disseminated to study participants and 
to patient group (eg, Association Québécoise de douleur 
chronique).
Ethics and dissemination
All the data collected and study related information will be 
securely stored in password- protected files for numeric data 
and in locked file cabinets for hard copies. Only study inves-
tigators will have access to the data at the completion of the 
trial. This study has received ethics approval at the Comité 
d’éthique de la recherche sectoriel en réadaptation et intégration sociale, 
CIUSS de la Capitale Nationale in June 2019 (#2020–1844 – 
CER CIUSSS- CN). Any modification of the protocol will be 
submitted to the ethics committee for approval and to  Clini-
calTrials. org. A study investigator will send information sheets 
to potential participants. They will then be able to have an 
informed discussion with the investigator about the informa-
tion provided in the information sheets. At the baseline visit, 
all participants will provide informed written consent prior to 
the beginning of the experiment, and they will be informed 
that they can withdraw at any moment during the study. 
Participants will also give written consent for the collection of 
data for ancillary studies (eg, MRI and sensory testing).
Results of the RCT will be published in a peer- reviewed 
journal, and deidentified data will be made available on 
a public repository at the time of publication. Results 
will also be disseminated through scientific meetings. 
The International Committee of Medical Journal Editors 
criteria for authorship will be followed, and no profes-
sional writer will be involved.
Participant withdrawal and adverse events
To minimise safety issues regarding rTMS intervention, 
we will follow safety guidelines and use a screening ques-
tionnaire.33 34 In addition, a visual monitoring of ‘prox-
imal’ motor evoked potentials in the trapezius muscle, 
which would indicate an intracortical spread of excitation, 
will be used.33 Any potential adverse events reported by 
participants will be monitored at the end of the 8- week 
intervention (eg, nature of the event, duration and need 
to see a health professional). The decision to continue 
the study will depend on the nature of the incident and 
the participant desire. A participant will be able to with-
draw from the study at any time and without justification. 
Previously collected data will be included in the analysis 
with the permission of the participant.
Timeline and feasibility
Recruitment started in September 2020 and is expected 
to be completed in September 2022. We expect to recruit 
at a rate of six participants per months, as a treatment 
facility entirely dedicated to this project is available. Also, 
the funding is secured by multiple grants from the Cana-
dian Pain Society, Pfizer Inc and Eli Lilly and Company, 
and the Canadian Institutes of Health Research.
DISCUSSION
This is the first RCT to investigate both repeated rTMS sessions 
and the combination of rTMS and MCE for the treatment of 
patients with CLBP. The poor efficacy of surgery or drugs, 
and their significant risks of adverse effects, underpins a need 
for conservative non- pharmacological interventions. As the 
previous studies using rTMS for CLBP have shown promising 
results20 21 and exercises are the most recommended inter-
vention in international guidelines,60 we believe their combi-
nation has the potential to produce a meaningful impact 
on pain and disability for patients with CLBP. This study has 
several strengths. First, it will provide robust evidence on the 
interest of rTMS alone or in association with MCE for the 
treatment of CLBP, up to a period of 6 months. The use of a 
sham rTMS coil and the control of blinding at the end of the 
study will efficiently control for the placebo effect of rTMS 
and allows to measure a true effect. Both participants and 
the physical therapists providing MCE will be blinded to the 
rTMS treatment. However, a limitation of this protocol might 
be the lack of blinding of the technician administering rTMS 
and the participants undergoing MCE due to the nature of 
the intervention. Nevertheless, as our main goal is to evaluate 
the contribution of rTMS (MCE have already been exten-
sively studied),25 an efficient blinding of rTMS is considered 
Table 2 Pseudofactorial design of the ExTraStim trial
MCE
Yes No








MCE, motor control exercises; rTMS, repetitive transcranial 
magnetic stimulation.
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the priority. A further limitation could be that this trial will 
be conducted at one research centre, limiting the gener-
alisability of the results, although the recruitment will be 
achieved through different processes as described previously.
This study provides the opportunity to determine the 
efficacy of these treatments/treatment combinations 
using a rigorous research protocol. rTMS is a non- invasive 
technique that is increasingly available for management 
of other conditions such as depression.61 If we establish 
its effectiveness, this device could contribute to the care 
provided to people with CLBP and reduce its economic 
and social impact through greater pain relief and 
improvement of functional capacity.
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